The purpose of the study was to examine the cost-effectiveness of managed care interventions with respect to prescriptions for chronic illness sufferers enrolled with a specific medical scheme. The illnesses included, were epilepsy, hypertension, diabetes and asthma. The managed care interventions applied were a prim ary discount; the use of preferred provider pharmacies, and drug utilization review. It was concluded that the managed care interventions resulted in some real cost savings.
INTRODUCTION

Research
E sca la tin g health care co s ts are especially a problem in the treatment of those who suffer from chronic illnesses. For the health in s u re r the annual e x p e n d itu re on a cu te and c h ro n ic medicines amounts to 30% of the total ann ua l c la im s (M a g e n n is:1 9 9 6 ). M edicines accounted for 8,5% of the South African gross national product in 1992 to 1993 (McIntyre, Bloom, Doherty and Brijlal 1995:16) . This is higher than for other countries, with an equivalent gross national product.
Approximately 75% of pharmaceutical p ro d u c ts are s o ld in S outh A frica according to a tender system, where the price of medication is reduced to below co st in any case (O pie & Steyn 1 995:1330) . This m eans th a t the o p p o rtu n ity to m ake a p ro fit on medication is shifted to the private sector, and the insured patient thus subsidises the government patient, by paying an exorbitant price for medication (Opie & Steyn 1995 :1330 Walters 1991:33) .
Currently, m anaged care, is used to describe a network of providers who have been given the resp on sibility of c o ordinating cost-effective health care, without compromising quality (Managed Care Information, Definition and Contract Considerations 1993:271; Ceslowitz 1993:366) .
The following managed care principles need to be applied in addressing the e xcessive c o s ts o f p h a rm a c e u tic a l treatm ent of chronic illnesses among privately insured patients:
• Networking. This means that a preferred provider supplies medication to the patient in collaboration with the health insurer/medical aid, on the basis of a contract that specifies, amongst other things, the level of service to be rendered and price agreements.
• Price negotiation. The preferred p ro v id e r s u p p lie s th e m e d ic a tio n a c c o rd in g to an a gre e d d is c o u n t structure.
• Drug utilization review. A review is done by the pharmacy on the prescription in order to control the cost thereof. It is an effort to reduce poly-pharmacy, a term used to describe a prescription which is so bulky that it becomes difficult for the patient to m anage. (Hamdy, Moore, Whalen, Donelly, Compton, Testerman, Haulsee and Hughes 1995:535) . Drug utilization review should not be done in isolation from the patients' diagnosis and other health care needs (Soumerai & Lipton 1995 :1641 .
Form ularies. A fo rm u la ry is a concatenated list of essential drugs that is used to narrow the margin of choice when prescribing, and therefore reducing th e o ve ra ll c o st o f p re s c rip tio n s (M cG ahan 1994:120) . The lis t is com prehensive and dynam ic and is aimed to promote doctors to prescribe in a cost-effective manner (Kongstvedt 1993:152) . There are fo u r typ e s of formularies ranging from an open one, to a very tightly managed one (Guiaquinta 1994:31) .
REASONS FOR THE STUDY
Purpose of the study
The purpose of the study was to examine the cost-containment effect of managed h ealth care on the o ve ra ll c o st of m e d ic a tio n ta ken to tre a t p a tie n ts suffering from four chronic illnesses in a specific medical insurance company:
• epilepsy • hypertension • diabetes • asthma The mechanisms used to contain costs were: • A discount on the price of medicines was negotiated. • A single preferred provider for the supply of the medication was selected • Drug utilization review on all new prescriptions was performed to search for opportunities to reduce the overall cost of prescriptions. Drug prices are rising higher than other health care prices and in 1991 rose two to three tim es higher than consum er inflation (Taylor 1993:33) . Not only are the prices rising, but the consum ption of medicines is also increasing (Giaquinta 1994:31) . There is a limitation on the available funds to pay for uncontrolled health care costs. Medical aids are folding because of this burden and should the costs of health care remain uncontrolled, the health insurer will suffer the same fate. M anaged h ealth care re g a rd in g medication control of patients suffering from ch ro n ic illnesses, needs to be assessed for what it really is.
RESEARCH QUESTIONS
The following questions were asked to establish whether care interventions are effective in containing the costs of chronic m edication prescriptions for asthma, epilepsy, hypertension and diabetes.
1.
How does the u tiliz a tio n of preferred providers influence the cost of chronic medication prescriptions? Do agreements between third party payers and preferred providers regarding the discount available on chronic medicines effectively reduce the cost of chronic medicines?
2.
A d voca te s of d ru g u tiliz a tio n review prom ote the concept of large savings that can be made on chronic prescriptions. What is the size of these savings?
3.
Does the effort involved in drug utilization review reduce the cost of c h ro n ic m e d ic a tio n p re s c rip tio n s significantly?
4.
Is managed care aimed at savings of m ed ica tio n costs, as w ell as the improvement in the quality of health care rendered?
5.
Does the quality of the service rendered by the preferred providers influence the cost of these prescriptions?
METHODOLOGY
A survey was used to examine the costs of long-term medication for the treatment of patients suffering from hypertension, epilepsy, diabetes and asthma. T hree m anaged care to o ls w ere implemented, namely a primary discount, drug utilization review, and the use of a preferred provider. The survey was used to d e s c rib e th e e ffe c t o f th e implementation of these managed care tools on the costs of the medication for the above-mentioned illnesses. The costs of the medicines for the months January to June 1995, were compared with those of the second half, of the same year. The managed care interventions were implemented as follows:
•
In the firs t half of the year, a primary discount, ranging between 16% and 35% was implemented in an attempt to reduce costs. For this purpose, one contract was introduced and another was in place with two postal pharmacies, Pharmacies A & B. The contracts with these two pharmacies was terminated on 30 June 1995. These two pharmacies were chosen as preferred providers of medicines for those members who had access to the Chronic Illness Benefit which covered medicines for specific chronic illnesses.
• From July to December another postal pharmacy, (Pharmacy C), was used as the preferred provider. In addition to performing drug utilization reviews on all prescriptions, this pharm acy also offered a discount of 35%.
• A comparison was made between the cost of medicines purchased at retail pharmacies and those bought from the preferred providers. This was done to see if the im p lem en ta tion of a d is c o u n t coup le d with drug u tilization review significantly reduced the cost of long-term medication.
Sample:
The sa m p le sizes fo r the d iffe re n t illnesses were as follows: 
RESEARCH INSTRUMENT
The research instrum ent was a que stionnaire designed by the researcher in order to keep track of the expenditure relating to the Chronic Illness Benefit. It was used to produce tw o com puter reports, nam ely the C hronic B enefit Expenditure Report, and the Network Utilization Report. A computer program mer discussed the researchers' specifi cations and questions to be asked in depth, prior to writing the programmes for the two reports. The Chronic Benefit Expenditure Report was d esign ed by the researcher to m onitor the utilization of the C hronic Illness Benefit on a monthly basis. When the report was first tested, it was found to be unstable because of its bulkiness. It was refined and tested a second time.
The report was printed twice for the data of one month, to check its stability. The Network Utilization Report was used to track the utilization of the preferred provider pharmacies. This report was also printed twice for the same month, to check the stability of the programme and its reliability.
RELIABILITY
The d a ta used fo r the s tu d y w ere captured from pharmacy claims. These claims are produced by a standardised computer programme used by pharma cists in South Africa. Data capturing is done by claims assessors who have been through a standard training programme where they are trained on how to capture the relevant data.
VALIDITY
Did the reports accurately measure the effects of managed care on the cost of amounts i n Rands medicines for the four chronic illnesses in the study? Confounding factors were dealt with as follows:
• Inflation. The prices of medicines increase in an erratic and unpredictable manner. For the purpose of the study, it was assumed that these weekly changes would not significantly influence the cost of the chronic m edicines, w ithin the period of study, which was one year.. New m edicines on the market. This was accounted for by identifying the medicines that were brought out during the year of study.
New generic medicines released on the market. This was accounted for by identifying them and their potential in flu e n ce on th e average c o s t of medicines per illness, per member.
Changes in illness severity. This was p a rtic u la rly a p ro b le m w ith asthmatics and was accounted for by random examining of the m edicines claimed for by asthm atics during the labile period. Figure 1 shows the gender distribution of the members who had access to the Chronic Illness Benefit with regard to the illnesses included in the study. As can be seen, there appears to be little difference between male and female members with hypertension. Conversely, Figure 1 , reflects a higher prevalence of female sufferers of epilepsy, and a higher 
FINDINGS
Gender profile
EPILEPSY
The data in Figure 2 show the patterns of savings made in relation to the costs of the two types of providers. Since the costs for the first half of the year were erratic, the savings were equally erratic. The savings averaged R146 per member per month for the first six months of 1995. This savings average increased to R220 per member per month for the second half of 1995, after the introduction of tighter control of medication ordering and drug utilisation review.
HYPERTENSION
This figure depicts the savings made from the discounts and drug utilisation review 
DIABETES
This figure demonstrates the patterns of expenditure and savings that were made on the cost of diabetic medication. The savings that were made as a result of discounts and drug utilisation review were erratic. The smallest savings were made in June and August. The savings becam e m ore c o n s is te n t as d ru g u tilis a tio n review w as d on e m ore The smallest saving that was made was R7 in June and the largest saving was R483 for December. The average monthly saving was R142 which was 40% of the retail average monthly cost of R352.
ASTHMA
This figure shows the asthmatic costs and savings for July to December 1995. The average cost per month per member for the preferred provider was R216 and for the retail pharmacy it was R276. The savings made by using a preferred provider were not high. They did not differ much from one half of the year to the other. It is possible to assume that drug utilisation review did not have an impact on the cost of these medicines. Perhaps the period of intervention was too short for any dramatic results to emerge.
FINDINGS RELATED TO THE QUALITY Of SERVICE RENDERED BY THE PREFERRED PROVIDERS
The quality of the sen/ices rendered by the three preferred providers was audited by way of random informal checking of claims; by a formal audit done by an assistant pharmacist who had experience o f d ru g u tiliz a tio n review and by m o n ito rin g and fo llo w in g up o f complaints about the preferred providers. The following were found:
• A number of administrative errors were found, such as incorrect memSavings bership numbers, wrong dates, wrong d e liv e ry a dd re sses, w ro n g p atie nt, incorrect charging. (Although these errors did not directly influence the cost of medicines, because they were corrected p rio r to paym ent, they did result in dissatisfaction among the patients who now had to interact unnecessarily with the pharmacy).
• A few prescriptions were found where an opportunity for drug utilization review was missed, but the number of these was insignificant.
• There were a few incidences of over-supply of medication.
Six incidents of dispensing errors were picked up.
• Service problem s w hich were experienced, were the following:
• late delivery of medication • dispensing errors • members ordered their medicines for delivery on a specific date and were kept waiting after the delivery date without notification.
The price the medical aid had to pay for the poor service by the provider, was calculated according to • the costs of the salary of the staff member who took the call and the time spent solving the problem • the price of the telephone call to the provider to ascertain what went wrong and to organize for it to be corrected, and • the cost of the stationary used to document the problem.
TABLE 1
The cost of R41.10 per day that was spent on co m p la in ts d id not s ig n ific a n tly influence the savings made as a result of using the preferred provider fo r the supply of m edicines. Where no real change o ccurre d in the cost of the m e d icin e s as a re s u lt o f the d ru g utilization review the 30% to 35% discount appeared to a bsorb the cost of the complaints. 
CONCLUSIONS
SAVINGS RESULTING FROM THE APPLICATION Of A PREFERRED PROVIDER AND DISCOUNT
• In the case of e p ile p s y and hypertension, a saving of 44% and 47% re s p e c tiv e ly was d e m o n stra te d per member per month. This was greater than the prim ary d isco u n t that had been agreed upon between the preferred providers and the medical aid.
Conversely, the saving made on diabetes and asthma was 27% and 29% respectively. This was less than the primary discount that was applied.
• In general term s savings were made as a result of the application of a prim ary discount, w ith tw o illnesses s h o w in g a low e r sa vin g th a n was expected, while the other two illnesses demonstrated a saving that was higher than was expected.
SAVINGS RESULTING FROM THE APPLICATION OF DRUG UTILISATION REVIEW ON CHRONIC PRESCRIPTIONS
An expected saving of 11 % was achieved for epilepsy. Drug utilisation did not s ig n ific a n tly a ffe c t the c o s t of hypertensive medicines. A significant saving was made on the cost of diabetic m edicines. Savings were lost on the
